Some of the major challenges of PD-1/PDL-1 inhibitors in MM relate to dysfunctional T cell phenotype having decreased effector capacity and immunosuppressive micro-environment created by myeloid derived suppressor cells (MDSCs) and regulatory T cells. Here, CD274 is linked to Miyoshi myopathy.